The Expanding Landscape of Primary Biliary Cirrhosis Therapeutics: Market Analysis and Investment Opportunities

Overview of Primary Biliary Cirrhosis and Market Significance Primary Biliary Cirrhosis (PBC), recently renamed Primary Biliary Cholangitis, is a rare progressive autoimmune liver disease characterized by inflammation and destruction of intrahepatic bile ducts. This condition primarily affects women in their 40s and 50s, with an approximately 9:1 female-to-male ratio. The Primary Biliary Cirrhosis market has gained increased attention from pharmaceutical developers due to growing awareness, improved diagnostic capabilities, and evolving treatment paradigms. Market Size and Growth Dynamics The global PBC therapeutics sector was valued at approximately $1.5 billion in 2024, with projections indicating a robust CAGR of 7.5% through 2030. This growth is driven by the increasing prevalence of PBC, estimated between 19 and 402 cases per million globally, with notably higher rates in Northern Europe and North America. The Primary Biliary Cirrhosis market size expansion is furt...